Over 70 Confirmed Delegates for North America’s Leading Biopharmaceutical Event
News Dec 02, 2010
Biomanufacturing Summit 2011, taking place from January 24-25 in Marriott Mission Valley, San Diego is set to unveil the latest strategies and technologies available to improve your operations and equip you with the tools needed to thrive in an increasingly competitive environment.
This year’s program is a mixture of cross industry case studies, streamed keynote sessions and interactive workshops with presentations from:
Matthew Stober, Global Head Vaccines & Diagnostics Technical Operations, Novartis Vaccines & Diagnostics Andy Ramelmeier, Vice President, Manufacturing, Process Development,, BioMarin Pharmaceuticals Joerg Heidrich, Senior Vice President & Global Head, Product Supply Biotech, Bayer Healthcare Wolfgang Noe, President, Bioprocess Development, Biogen Idec
An integral part of the event is the pre-arranged one-to-one meetings sessions between delegates and solution providers. These meetings take the guess work out of networking, allow knowledge sharing, building of contact lists and potential for lucrative business contracts.
About the Biomanufacturing Summit 2011: Taking place over two days from January 24-25, 2011 at the Marriott Mission Valley, San Diego, the summit brings together 200+ senior level industry professionals working within manufacturing, process development and product operations. Confirmed delegates include representatives from Pfizer Inc, Sanofi Pasteur Biologics and Bayer Healthcare. Key sponsors include Merck Biomanufacturing Network, Bioproduction Group Inc. and Aegis Analytical Corporation. Find out more at http://www.biomanufacturingsummit.com
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE